8-K: Allogene Therapeutics Expands Collaboration with Foresight Diagnostics for Companion Diagnostic Development

Allogene Therapeutics and Foresight Diagnostics amend their strategic collaboration to develop a companion diagnostic assay in multiple regions, with Allogene funding $37.3 million.

Summary

• Allogene Therapeutics has entered into an Amended and Restated Strategic Collaboration Agreement with Foresight Diagnostics.
• The agreement expands their existing collaboration to develop Foresight's MRD assay as a companion diagnostic for Allogene's cema-cel in the EU, UK, Canada, and Australia.
• Allogene will fund approximately $37.3 million for MRD assay development, milestone payments for U.S., and certain international regulatory submissions and clinical sample testing.
• Both parties will use commercially reasonable efforts to obtain regulatory approval for their respective products.
• The agreement does not change each party's ownership of their background intellectual property rights or termination rights.

Sentiment

Score: 7

Explanation: The announcement is positive as it expands a collaboration and secures funding for a key development program. The sentiment is moderately positive as it represents progress but also involves financial commitment and regulatory risk.

Positives

• The expanded collaboration allows for the development of a companion diagnostic, potentially improving the efficacy and safety of Allogene's cema-cel.
• Funding of $37.3 million demonstrates Allogene's commitment to the collaboration and the development of cema-cel.
• The collaboration targets multiple international markets, expanding the potential reach of both companies' products.

Risks

• The success of the collaboration depends on both parties' ability to obtain regulatory approval for their respective products.
• The development of the MRD assay and cema-cel may face unforeseen challenges or delays.
• The $37.3 million funding commitment represents a significant investment for Allogene.

Future Outlook

The parties have agreed to use commercially reasonable efforts to obtain regulatory approval of their respective products and to perform activities assigned or allocated to it under the work plan.

Management Comments

• David Chang, M.D., Ph.D., President and Chief Executive Officer, signed the report on behalf of Allogene Therapeutics, Inc.

Industry Context

Companion diagnostics are becoming increasingly important in personalized medicine, guiding treatment decisions and improving patient outcomes. This collaboration reflects a growing trend in the pharmaceutical industry to develop targeted therapies with corresponding diagnostic tools.

Comparison to Industry Standards

• Many pharmaceutical companies collaborate with diagnostic firms to develop companion diagnostics.
• Roche partners with Foundation Medicine, and Novartis partners with Qiagen.
• The $37.3 million investment is within the typical range for such collaborations, but the specific terms depend on the stage of development and the scope of the agreement.

Stakeholder Impact

• Shareholders may view the expanded collaboration positively, as it could lead to improved treatment options and increased market access.
• Employees of both companies will be involved in the development and regulatory approval process.
• Patients may benefit from the availability of a companion diagnostic that helps guide treatment decisions.

Next Steps

• The parties will work to develop the MRD assay and seek regulatory approval in the EU, UK, Canada, and Australia.
• Clinical sample testing will be conducted to validate the assay's performance.

Key Dates